Lv4
500 积分 2021-10-19 加入
First-in-human randomized study of RNAi therapeutic RG6346 for chronic hepatitis B virus infection
6天前
已完结
OS-030 Efficacy and safety of xalnesiran with and without an immunomodulator in virologically suppressed participants with chronic hepatitis B: end of study results from the phase 2, randomized, controlled, adaptive, open-label platform study (PIRANGA)
7天前
已完结
Effects of multiple-dose pegylated interferon alfa-2b on the activity of drug-metabolizing enzymes in persons with chronic hepatitis C
9天前
已完结
LBP-008 Safety, tolerability, and remarkable hepatitis B surface antigen reduction in chronic hepatitis B patients treated with BW-20507
29天前
已关闭
First-in-human randomized study of RNAi therapeutic RG6346 for chronic hepatitis B virus infection
29天前
已完结
Control of Hepatitis B Virus with Imdusiran, a Small Interfering RNA Therapeutic
29天前
已完结
Pharmacokinetics, Safety, and Tolerability of the siRNA JNJ‐73763989 in Healthy Chinese Adult Participants
1个月前
已完结
Prediction of Interspecies Translation for Targeting Delivery Coefficients of GalNAc-siRNA Silencing Apolipoprotein C-III Using a Mechanistic Minimal Physiologically Based Pharmacokinetic/Pharmacodynamic Model
3个月前
已完结
WED-389 Pharmacokinetics and safety of the monoclonal antibody tobevibart (VIR-3434) administered as monotherapy or in combination with the small interfering RNA elebsiran (VIR-2218) in cirrhotic participants with mild hepatic impairment
3个月前
已关闭
VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study
3个月前
已完结
皖公网安备34019202002308
